Cannabinoid Product Kills Thyroid Cancer Cells by Activating Tumor Suppressor Genes

The cannabinoid product BRF1A decreased K1 papillary thyroid cancer cell viability dose- and time-dependently. Within 24 hours, it increased TP53 gene expression (tumor suppressor) while decreasing BCL-2 (anti-apoptotic) and c-Myc (proliferation) gene expression, suggesting a pro-apoptotic mechanism.

In vitro study using K1 papillary thyroid cancer cell line derived from metastatic well-differentiated PTC. BRF1A co-cultured with cells at 37°C. Cell viability assessed by trypan blue exclusion. Gene expression measured by qRT-PCR at 24 and 48 hours.

Papillary thyroid carcinoma is the most common thyroid cancer. While surgery is effective, non-invasive therapeutic options are being explored. This study provides initial evidence that cannabinoids may affect thyroid cancer cells through well-characterized anti-cancer pathways.

The p53/BCL-2/c-Myc pathway is a well-established cancer signaling axis. Showing cannabinoid modulation of these specific genes in thyroid cancer adds to the growing preclinical evidence of cannabinoid anti-cancer properties, though translation to clinical use remains distant.

Single cell line in vitro study. Proprietary cannabinoid product (BRF1A) — specific composition unclear. No comparison to standard treatments. No in vivo validation. Cannot predict clinical efficacy from cell culture results.